QTORIN Rapamycin 3.9% anhydrous gel
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for QTORIN Rapamycin 3.9% anhydrous gel, covering 2022-12-09 to 2022-12-09. Get the full timeline:
Most recent: Clinical Trial Update: A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita [Phase 3]